ArticleJMIR mHealth and uHealth2020
ReMindCare App for Early Psychosis: Pragmatic Real World Intervention and Usability Study.
Article in JMIR mHealth and uHealth, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 7 syntheses or guidelines pooled it, 24 citations in OpenAlex.
- Exploring global efforts in mental health screening and early detection.Frontiers in psychiatry · 2026Pooled it
- Smartphone apps for mental health: systematic review of the literature and five recommendations for clinical translation.BMJ open · 2025Pooled it
- Barriers and Facilitators of User Engagement With Digital Mental Health Interventions for People With Psychosis or Bipolar Disorder: Systematic Review and Best-Fit Framework Synthesis.JMIR mental health · 2025Pooled it
- Adverse Events Reporting in Digital Interventions Evaluations for Psychosis: A Systematic Literature Search and Individual Level Content Analysis of Adverse Event Reports.Schizophrenia bulletin · 2024Pooled it
- Opportunities and challenges in leveraging digital technology for mental health system strengthening: a systematic review to inform interventions in the United Arab Emirates.BMC public health · 2024Pooled it
- Mobile health in the specific management of first-episode psychosis: a systematic literature review.Frontiers in psychiatry · 2023Pooled it
- Factors Influencing Adherence to mHealth Apps for Prevention or Management of Noncommunicable Diseases: Systematic Review.Journal of medical Internet research · 2022Pooled it
- "It's like having a friend in your pocket." the service user experience of the Actissist digital health intervention for early psychosis: a qualitative study.BMC psychiatry · 2025Trial
- Smartphone Apps and Digital Tools for Managing Schizophrenia and Psychotic Disorders: A Clinical Review.Focus (American Psychiatric Publishing) · 2025Review
- Mobile Therapeutic Attention for Treatment-Resistant Schizophrenia (m-RESIST) Solution for Improving Clinical and Functional Outcomes in Treatment-Resistant Schizophrenia: Prospective, Multicenter Efficacy Study.JMIR human factors · 2025Article
- Mental Health Professionals' Technology Usage and Attitudes Toward Digital Health for Psychosis: Comparative Cross-Sectional Survey Study.JMIR mental health · 2025Article
- Digital Interventions for the Rehabilitation of First-Episode Psychosis: An Integrated Perspective.Brain sciences · 2025Review
- Implementing Technologies to Enhance Coordinated Specialty Care Framework: Implementation Outcomes From a Development and Usability Study.JMIR formative research · 2023Article
- A Mobile Health App (ChillTime) Promoting Emotion Regulation in Dual Disorders: Acceptability and Feasibility Pilot Study.JMIR formative research · 2023Article
- Accessibility and availability of smartphone apps for schizophrenia.Schizophrenia (Heidelberg, Germany) · 2022Article
- User engagement in mobile apps for people with schizophrenia: A scoping review.Frontiers in digital health · 2022Article
- Participant Engagement and Symptom Improvement: Aripiprazole Tablets with Sensor for the Treatment of Schizophrenia.Patient preference and adherence · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundeHealth interventions are widely used in clinical trials and increasingly in care settings as well; however, their efficacy in real-world contexts remains unknown. ReMindCare is a smartphone app that has been systematically implemented in a first episode of psychosis program (FEPP) for patients with early psychosis since 2018.
objectiveThe objective of this study was to assess the efficacy of ReMindCare after 19 months of use in the clinic and varying use by individual patients.
methodsThe integration of the ReMindCare app into the FEPP started in October 2018. Patients with early psychosis self-selected to the app (ReMindCare group) or treatment as usual (TAU group). The outcome variables considered were adherence to the intervention and number of relapses, hospital admissions, and visits to urgent care units. Data from 90 patients with early psychosis were analyzed: 59 in the ReMindCare group and 31 in the TAU group. The mean age of the sample was 32.8 (SD 9.4) years, 73% (66/90) were males, 91% (83/90) were White, and 81% (74/90) were single.
resultsSignificant differences between the ReMindCare and TAU groups were found in the number of relapses, hospitalizations, and visits to urgent care units, with each showing benefits for the app. Only 20% (12/59) of patients from the ReMindCare group had a relapse, while 58% (18/31) of the TAU patients had one or more relapses (χ
conclusionsTo our knowledge, this is the first eHealth intervention that has preliminarily proven its benefits in the real-world treatment of patients with early psychosis. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): RR2-10.1111/eip.12960.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.